Skip to main content
Erschienen in: Cancer Causes & Control 2/2020

01.02.2020 | Original Paper

Sexual orientation and benign breast disease in a cohort of U.S. women

verfasst von: Brittany M. Charlton, Leslie V. Farland, Ulrike Boehmer, Rulla M. Tamimi, Laura C. Collins, Nicole A. VanKim, Elizabeth R. Bertone-Johnson, Jennifer Potter, Vishnudas Sarda, S. Bryn Austin

Erschienen in: Cancer Causes & Control | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Several studies indicate that sexual minority (e.g., bisexual, lesbian) women may be at an increased risk for breast cancer. However, we know little about how risk factors, such as benign breast disease (BBD)—which can confer nearly a fourfold breast cancer risk increase—may vary across sexual orientation groups.

Methods

Among Nurses’ Health Study II participants followed from 1989 to 2013 (n = 99,656), we investigated whether bisexual and lesbian women were more likely than heterosexual women to have breast cancer risk factors including a BBD diagnosis (self-reported biopsy or aspiration confirmed, n = 11,021). Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (CI).

Results

Compared to heterosexuals, sexual minority participants more commonly reported certain breast cancer risk factors including increased alcohol intake and nulliparity. However, sexual minority participants were more likely than heterosexuals to have certain protective factors including higher body mass index and less oral contraceptive use. When evaluating age- and family history-adjusted rates of BBD diagnoses across sexual orientation groups, bisexual (HR 1.04, 95% CI [0.78, 1.38]) and lesbian (0.99 [0.81, 1.21]) women were just as likely as heterosexuals to have a BBD diagnosis. Results were similar after adjusting for other known breast cancer risk factors.

Conclusions

In this cohort of women across the U.S., sexual minorities were more likely than heterosexuals to have some breast cancer risk factors—including modifiable risk factors such as alcohol intake. Heterosexual, bisexual, and lesbian women were equally as likely to have a BBD diagnosis.
Literatur
1.
Zurück zum Zitat Meads C, Moore D (2013) Breast cancer in lesbians and bisexual women: systematic review of incidence, prevalence and risk studies. BMC Public Health 13:1127CrossRef Meads C, Moore D (2013) Breast cancer in lesbians and bisexual women: systematic review of incidence, prevalence and risk studies. BMC Public Health 13:1127CrossRef
8.
Zurück zum Zitat Cochran S, Mays V, Bowen D et al (2001) Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. Am J Public Health 91:591–597CrossRef Cochran S, Mays V, Bowen D et al (2001) Cancer-related risk indicators and preventive screening behaviors among lesbians and bisexual women. Am J Public Health 91:591–597CrossRef
9.
Zurück zum Zitat Valanis BG, Bowen DJ, Bassford T et al (2000) Sexual orientation and health: comparisons in the women’s health initiative sample. Arch Fam Med 9:843–853CrossRef Valanis BG, Bowen DJ, Bassford T et al (2000) Sexual orientation and health: comparisons in the women’s health initiative sample. Arch Fam Med 9:843–853CrossRef
11.
Zurück zum Zitat Rankow EJ (1995) Breast and cervical cancer among lesbians. Womens Health Issues 5:123–129CrossRef Rankow EJ (1995) Breast and cervical cancer among lesbians. Womens Health Issues 5:123–129CrossRef
13.
Zurück zum Zitat Dyrstad SW, Yan Y, Fowler AM, Colditz GA (2015) Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 149:569–575CrossRef Dyrstad SW, Yan Y, Fowler AM, Colditz GA (2015) Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat 149:569–575CrossRef
14.
Zurück zum Zitat Marshal MP, Friedman MS, Stall R et al (2008) Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction 103:546–556CrossRef Marshal MP, Friedman MS, Stall R et al (2008) Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction 103:546–556CrossRef
22.
Zurück zum Zitat Lunn M, McNeil D (1995) Applying cox regression to competing risks. Biometrics 51:524–532CrossRef Lunn M, McNeil D (1995) Applying cox regression to competing risks. Biometrics 51:524–532CrossRef
23.
Zurück zum Zitat Graham R, Berkowitz B, Blum R, Bockting W, Bradford J, de Vries B, Makadon H (2011) The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Institute of Medicine, Washington (DC) Graham R, Berkowitz B, Blum R, Bockting W, Bradford J, de Vries B, Makadon H (2011) The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Institute of Medicine, Washington (DC)
24.
Zurück zum Zitat Solarz AL (1999) Lesbian health: current assessment and directions for the future. Institute of Medicine (US) Committee on Lesbian Health Research Priorities, Washington (DC). Solarz AL (1999) Lesbian health: current assessment and directions for the future. Institute of Medicine (US) Committee on Lesbian Health Research Priorities, Washington (DC).
Metadaten
Titel
Sexual orientation and benign breast disease in a cohort of U.S. women
verfasst von
Brittany M. Charlton
Leslie V. Farland
Ulrike Boehmer
Rulla M. Tamimi
Laura C. Collins
Nicole A. VanKim
Elizabeth R. Bertone-Johnson
Jennifer Potter
Vishnudas Sarda
S. Bryn Austin
Publikationsdatum
01.02.2020
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 2/2020
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01258-z

Weitere Artikel der Ausgabe 2/2020

Cancer Causes & Control 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.